The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association.

Journal Article (Journal Article;Review)

There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

Full Text

Duke Authors

Cited Authors

  • Musunuru, K; Ingelsson, E; Fornage, M; Liu, P; Murphy, AM; Newby, LK; Newton-Cheh, C; Perez, MV; Voora, D; Woo, D; American Heart Association Committee on Molecular Determinants of Cardiovascular Health of the Council on Functional Genomics and Translational Biology and Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council,

Published Date

  • August 2017

Published In

Volume / Issue

  • 10 / 4

PubMed ID

  • 28760750

Electronic International Standard Serial Number (EISSN)

  • 1942-3268

Digital Object Identifier (DOI)

  • 10.1161/HCG.0000000000000037


  • eng

Conference Location

  • United States